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than NoTx (ORs 2.3 & 5.4 respectively). Also, SSanlg was 
better than NoTx (OR 1.7). 
 
Conclusion: RT20IVGC is the best treatment followed by IVGC 
and CysprnPOGC per this NMA. Also, RT20RBGCI and SSanlg 
were better than NoTx. 
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Purpose or Objective: Recurrent head and neck cancer 
(HNC) after radiotherapy or surgery has many problems about 
salvage treatment options such as surgery, chemotherapy and 
radiation therapy. Stereotactic radiotherapy is one of the 
treatment options for inoperable patients. However, in many 
cases, salvage radiation (SRT) is considered as a re-
irradiation, and the treatment results of salvage radiation 
with a definitive dose for recurrent HNC are still insufficient. 
This analysis was done to reveal the treatment results and 
prognostic factors in SRT for both of locoregional and distant 
recurrences, with definitive treatment dose. 
 
Material and Methods: One hundred and three patients with 
43 local, 23 regional and 36 distant recurrences were treated 
with stereotactic radiotherapy for definitive treatment 
purpose. Treatment period was between May 1998 and July 
2014. Eighteen to 70 Gy were delivered in 3 to 20 fractions. 
Treatments were delivered with CyberKnife or Novalis 
treatment system. There were 59 patients with squamous 
cell carcinoma, 8 with adenoid cystic carcinoma, 7 with 
papillary adenocarcinoma and 26 patients with other 
histlogical type. 
 
Results: Median follow up period of survivors was 17 months 
(range 0-103), and the median survival time of all patients 
was 23 months. At 3 years, actuarial overall survival rate (OS) 
was 37%, 33% and 23%, and median survival time was 30, 26 
and 20 months for local, regional and distant recurrence, 
respectively (p =0.638). OS was significantly better in the 
patients with oligo-recurrence (p<0.001) or to whom SRT 
were done for a lesion previously untreated by surgery 
(p=0.001). Cox regression analysis indicated that factors of 
oligo-recurrence and histology except for squamous 
carcinoma had significant influence on OS. The favorable 
group having both of the two factors (n=23) showed excellent 
5 year survival as 73 % compared with 15% of unfavorable 
group. 
 
Conclusion: This study showed that SRT with definitive dose 
achieved equivalent survival regardless of recurrent site and 
revealed two prognostic factors of oligo-recurrence and non-
squamous carcinoma in the SRT for recurrent HNC. 
 
Poster: Clinical track: CNS  
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Purpose or Objective: Single session radiosurgery (SRS) and 
staged radiosurgery (sSRS) have been performed in primary 
and adjuvant settings for intracranial meningioma. Although, 
different aspects of SRS and sSRS are still controversial above 
all regarding timing, prescription doses and fractionation of 
delivery. So far there are no definitive data about treatment-
related symptom control and toxicity and categorization. The 
aim of this systematic review is to summarize the data on the 
long-term efficacy and safety of SRS and sSRS for meningioma 
patients. 
 
Material and Methods: Medline and Embase databases were 
searched for relevant studies published until April 2015. 
Experimental and observational studies focused on SRS and 
sSRS for intracranial WHO grade I and II meningioma were 
included. Studies enrolling a number of patients inferior to 
five for each arm (for comparative studies) or overall (for 
non-comparative studies) were excluded. Studies including 
patients with malignant meningioma (WHO grade III), radio-
induced meningioma or patients who had previously 
undergone brain radiation therapy were excluded from our 
review. Studies including both benign and malignant 
meningiomas were considered eligible, provided that results 
were reported separately, according to histo-pathological 
subtype. The primary outcomes were disease control and 
progression-free-survival. The secondary outcomes were 
symptom control and radiation-induced toxicity. 
 
Results: Thirty-four studies fulfilled eligibility criteria. Only 
two studies were about sSRS. The estimate of disease control 
rate ranged from 87.0% to 100.0% at 5 years and from 67.0% 
to 100.0% at 10 years. The PFS rate ranged from 78.0% to 
98.9% and from 53.1% to 97.2% at 5 and 10 years, 
respectively. No meta-analysis could be performed.We meta-
analyzed symptom control and toxicity data. The overall 
frequency of symptom control was 92.3% (95% CI:88.4-95.6%), 
the overall toxicity was 8.1% (95% CI:5.2-11.5%). The overall 
relative frequency of patients with toxicity of 8.1% (95% CI: 
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5.2-11.5%), again with high heterogeneity (I2=81.0%) among 
studies. 
 
Conclusion: All included studies have shown some 
limitations: most of them were retrospective and all were 
non-comparative; many of them were carried out in absence 
of a rigorous methodology and only few reported a measure 
of variability for the primary endpoint. Despite these 
limitations, we can conclude that SRS appears safe and 
effective treatment for intracranial meningioma. 
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Purpose or Objective: patients (pts) with 1-4 brain 
metastases (BM) from non-small cell lung cancer (NSCLC) 
submitted to radiosurgery (SRS) alone were retrospectively 
evaluated. 
 
Material and Methods: 130 pts with 207 BM were identified. 
Pts were treated with a 5-MV linear accelerator fitted with a 
commercial dynamic μMLC. Doses were prescribed to 
isocentre so that at least the 90% isodose line encompassed 
the target volume. Doses were chosen according to maximum 
diameter of the tumor as suggested by RTOG Protocol 90-05. 
Male/female ratio was 90/40, median age was 64 years 
(range, 31-86). Median KPS was 100% (range, 70-100). 42/130 
(32%) pts had extracranial metastases, 83 (64%) pts had a 
controlled systemic disease, and 47 (36%) progressive 
disease. Neurologic functional score was generally good (NFS 
= 0), and only 15 (11.5%) pts had an NFS = 3 or 4. Relapse was 
defined “in-field” when more than 95% of the recurrence 
volume was within the original 50% isodose, and “out-field” 
in the other cases.  
 
Results: In 82 (63%) pts there was only one BM, in remaining 
48 (37%) 2-4 BM with a median volume of 0.8cc (range, 0.09-
25) Median prescribed dose was 23 Gy (range, 12-25). At a 
median follow-up of 67 months (range, 24-110), 123 (95%) pts 
with 197 (95%) BM were evaluable. Local control, evaluated 3 
months after SRS, was obtained in 95% of lesions: there were 
complete remission in 50 (25%), partial remission in 77 (39%), 
stable disease in 62 (31%), and progression in 13 (5%) BM. 
During follow up, 63 (51%) pts had no brain progression of 
disease, 11 (9%) had in-field relapse, 40 (33%) out-field 
relapse, and 9 (7%) in- and out-field relapse. Of 60 (49%) 
relapsing pts, 37 (62%) were retreated: 19 with SRS, 15 with 
whole brain radiotherapy (WBRT), 2 with fractionated 
stereotactic radiotherapy, and 1 with surgery and WBRT. No 
SRS-induced late toxicity was registered. At the time of 
analysis, 119/123 patients (97%) had died, 40 (34%) for brain 
progression, 72 (60%) for systemic progression and 7 (6%) for 
non-oncological causes. The median overall survival was 13 
months, deaths from brain progression occurred after a 
median time of 51 months, while from systemic progression 
after 19 months. 
 
Conclusion: SRS without upfront WBRT is an effective 
treatment of BM from NSCLC. Since that our results are 
similar to the best published data on SRS plus WBRT, SRS 
alone could be considered the treatment of choice in this 
setting. 
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Purpose or Objective: To estimate the clinical results of 
hypofractionated stereotactic radiotherapy (HSR) alone or in 
combination with stereotactic radiosurgery (SRS) for the 
treatment of brain metastases using different radiation 
devices, which provide precise delivery of a high radiation 
dose to the target. 
 
Material and Methods: Between November 2010 and July 
2015, 257 patients with brain metastases were treated by 
HSR alone or simultaneous application of two stereotactic 
radiation techniques (SRS plus HSR) at the Radiosurgical 
Centre of IIBS (Saint Petersburg, Russia). Radiation treatment 
was performed with Gamma Knife 4C and Perfexion (Elekta 
AB, Stockholm, Sweden), Cyber Knife (Accuray, Sunnyvale, 
CA, USA) and linear accelerator TrueBeam STX (Varian 
Medical Systems, Palo Alto, CA) equipped with the BrainLAB 
Exac Trac system. The indications for HSR were determined 
by the presence of large volume lesions or proximity to 
critical brain structures. Patients with multiple brain 
metastases were subjected to a combination of HSR and SRS. 
Radiation schemes were selected depending on the number 
of metastases, size, location, proximity to critical brain 
structures, histological type of primary cancer and the 
patient’s general condition. SRS was performed with the 
marginal dose of 18 – 24 Gy at 40 – 90 % isodose and HSR was 
performed with the total dose of 24, 27 or 30 Gy in 3 
fractions. Following treatment the patients underwent 
control MRI examination with standard protocols (2 mm T2 
and 1 mm T1 with double contrast enhancement) at 8 weeks 
and then every 3 months. The median follow-up period was 6 
months. 
 
Results: The study revealed that the application of 
hypofractionated stereotactic radiotherapy for the treatment 
of large volume or critically located brain metastases 
provides a high level of local control (12-month local control 
rate was 83 %). Complications in the form of radiation 
necrosis occured in 15 % of patients at a median of 6 months 
after treatment. The median overall survival for the entire 
patient cohort was 9 months. There was no statistically 
significant difference in the median survival of the patients 
receiving HSR alone and those receiving HSR plus SRS. The 
best results were obtained in patients belonging to the first 
RPA-class who achieved two-year survival in 70 % of the 
cases. The advantage of combining SRS and HSR is the 
possibility to deliver high radiation doses to large volume 
lesions, without exceeding the brain’s tolerance. HSR allows 
one to achieve a rapid shrinkage of large volume tumors, 
which considerably improves the patient’s neurological 
condition. 
 
Conclusion: High-dose stereotactic radiation is a safe and 
effective method for controlling brain metastases. A 
combined application of SRS and HSR is a viable treatment 
strategy for patients with multiple brain metastases who 
have at least one large lesion or a lesion located in/near 
critical brain structures. 
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Purpose or Objective: We hypothesized that hippocampal-
sparing radiotherapy using volumetric modulated arc therapy 
(VMAT) could preserve cognitive function of the patients with 
primary brain tumor treated with brain radiotherapy.  
 
Material and Methods: We prospectively collected patients 
who were diagnosed with primary brain tumor and treated 
with brain radiotherapy from March 2014 to April 2015. Brain 
radiotherapy was delivered using VMAT planning technique 
with inclined head position. Optimization criteria for the 
